Partner Howard Young spoke with The Legal Intelligencer about the potential for an uptick in life sciences transactions under the incoming Trump-Vance Administration. Howard noted that policy decisions by the new administration are likely to influence the pace of deals in the sector.
“There’s been a lot of capital on the sidelines that is ready to be deployed and particularly if there’s a little more certainty in terms of antitrust review … [and] on how the federal agencies will view the potential mergers and affiliations and the like,” Howard said. “Broadly speaking and assuming the cost of capital doesn’t go up … generally speaking we expect more robust dealflow.”